Literature DB >> 31391935

Autoimmune Hepatitis Beyond Steroids: Effective Trial Design and Attention to Quality of Life.

Christoph Schramm1.   

Abstract

Entities:  

Year:  2019        PMID： 31391935      PMCID： PMC6677095          DOI： 10.1002/cld.816

Source DB:  PubMed          Journal:  Clin Liver Dis (Hoboken)        ISSN： 2046-2484


× No keyword cloud information.
  10 in total

1.  EASL Clinical Practice Guidelines: Autoimmune hepatitis.

Authors: 
Journal:  J Hepatol       Date:  2015-09-01       Impact factor: 25.083

2.  Usefulness of biochemical remission and transient elastography in monitoring disease course in autoimmune hepatitis.

Authors:  Johannes Hartl; Hanno Ehlken; Marcial Sebode; Moritz Peiseler; Till Krech; Roman Zenouzi; Johann von Felden; Christina Weiler-Normann; Christoph Schramm; Ansgar W Lohse
Journal:  J Hepatol       Date:  2017-11-24       Impact factor: 25.083

3.  Transient elastography in autoimmune hepatitis: Timing determines the impact of inflammation and fibrosis.

Authors:  Johannes Hartl; Ulrike Denzer; Hanno Ehlken; Roman Zenouzi; Moritz Peiseler; Marcial Sebode; Sina Hübener; Nadine Pannicke; Christina Weiler-Normann; Alexander Quaas; Ansgar W Lohse; Christoph Schramm
Journal:  J Hepatol       Date:  2016-05-26       Impact factor: 25.083

4.  Budesonide induces remission more effectively than prednisone in a controlled trial of patients with autoimmune hepatitis.

Authors:  Michael P Manns; Marek Woynarowski; Wolfgang Kreisel; Yoav Lurie; Christian Rust; Elimelech Zuckerman; Matthias J Bahr; Rainer Günther; Rolf W Hultcrantz; Ulrich Spengler; Ansgar W Lohse; Ferenc Szalay; Martti Färkkilä; Markus Pröls; Christian P Strassburg
Journal:  Gastroenterology       Date:  2010-06-22       Impact factor: 22.682

5.  Autoimmune hepatitis in Denmark: incidence, prevalence, prognosis, and causes of death. A nationwide registry-based cohort study.

Authors:  Lisbet Grønbæk; Hendrik Vilstrup; Peter Jepsen
Journal:  J Hepatol       Date:  2013-10-26       Impact factor: 25.083

6.  Bone loss in autoimmune chronic active hepatitis on maintenance corticosteroid therapy.

Authors:  A J Stellon; A Davies; J Compston; R Williams
Journal:  Gastroenterology       Date:  1985-11       Impact factor: 22.682

7.  Late results of the Royal Free Hospital prospective controlled trial of prednisolone therapy in hepatitis B surface antigen negative chronic active hepatitis.

Authors:  A P Kirk; S Jain; S Pocock; H C Thomas; S Sherlock
Journal:  Gut       Date:  1980-01       Impact factor: 23.059

8.  Unmet needs and new models for future trials in autoimmune hepatitis.

Authors:  David Jones; Michael P Manns; Luigi Terracciano; Michael Torbenson; John M Vierling
Journal:  Lancet Gastroenterol Hepatol       Date:  2018-04-06

9.  Health-related quality of life, depression, and anxiety in patients with autoimmune hepatitis.

Authors:  Christoph Schramm; Inka Wahl; Christina Weiler-Normann; Katharina Voigt; Christiane Wiegard; Claudia Glaubke; Elmar Brähler; Bernd Löwe; Ansgar W Lohse; Matthias Rose
Journal:  J Hepatol       Date:  2013-11-14       Impact factor: 25.083

10.  The Impact of Autoimmune Hepatitis and Its Treatment on Health Utility.

Authors:  Lin Lee Wong; Holly F Fisher; Deborah D Stocken; Stephen Rice; Amardeep Khanna; Michael A Heneghan; Ye Htun Oo; George Mells; Stuart Kendrick; Jessica Katharine Dyson; David E J Jones
Journal:  Hepatology       Date:  2018-10       Impact factor: 17.425
  10 in total
  1 in total

1.  Health-related quality of life in patients with autoimmune hepatitis.

Authors:  Maurice Michel; Francesca Spinelli; Annette Grambihler; Christian Labenz; Michael Nagel; Leonard Kaps; Yvonne Huber; Peter R Galle; Marcus-Alexander Wörns; Jörn M Schattenberg
Journal:  Qual Life Res       Date:  2021-05-12       Impact factor: 4.147
  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.